



邹劲林, 李振东, 叶友强, 孙华宾. 参芪扶正注射液联合FOLFOX4对II/III期大肠癌患者免疫功能和生活质量的影响[J]. 中国现代应用药学, 2012, 29(8):755-758

参芪扶正注射液联合FOLFOX4对II/III期大肠癌患者免疫功能和生活质量的影响

Observation on the Influence of Shenqifuzheng Injection on Immune Function and the Quality of Life of the Patients with Stage II/III Colorectal Cancer with Chemotherapy

投稿时间: 2011-11-14 最后修改时间: 2012-04-08

DOI:

中文关键词: [参芪扶正注射液](#) [大肠癌](#) [免疫功能](#) [生活质量](#)

英文关键词: [Shenqifuzheng injection](#) [colorectal cancer](#) [immune function](#) [quality of life](#)

基金项目: Observation on the influence of Shenqifuzheng injection combined with FOLFOX4 on immune function and the quality of life of the patients with stage II/III colon cancer with chemotherapy

作者	单位	E-mail
邹劲林	中山大学附属第五医院普外科, 广东 珠海 519000	taxol@qq.com
李振东	中山大学附属第五医院普外科, 广东 珠海 519000	
叶友强	中山大学附属第五医院普外科, 广东 珠海 519000	
孙华宾*	中山大学附属第五医院普外科, 广东 珠海 519000	tax010900@sina.com

摘要点击次数: 106

全文下载次数: 114

中文摘要:

目的 探讨参芪扶正注射液对II/III期大肠癌化疗患者免疫功能和生活质量的影响。方法 将89例II/III期大肠癌患者随机分为单纯化疗组和联合治疗组。单纯化疗组给予FOLFOX4化疗, 联合治疗组给予FOLFOX4化疗+参芪扶正注射液 250 mL静脉滴注, 1次·d⁻¹, 连续7 d。观察Karnofsky评分、细胞免疫功能指标(检测CD₃⁺、CD₄⁺、CD₈⁺T细胞、NK细胞(CD₁₆⁺、CD₅₆⁺)的百分数、CD₄⁺/CD₈⁺比值、IgG、IgA和IgM)和化疗不良反应。结果 联合治疗组Karnofsky评分好于单纯化疗组(P<0.01)。治疗后第7天, 联合治疗组对CD₃⁺、CD₄⁺、CD₄⁺/CD₈⁺、NK、IgG、IgA和IgM高于单纯化疗组, 但是对CD₈⁺无明显作用。联合治疗组免疫球蛋白明显高于单纯化疗组。联合治疗组化疗不良反应少且相对较轻, 主要是I~II级不良反应, 两组不良反应的差异具有统计学意义(P<0.05)。结论 参芪扶正注射液能降低II/III期大肠癌FOLFOX4化疗不良反应, 改善身体机能, 提高患者细胞免疫功能, 从而增强患者对化疗的依从性, 对化疗起协调作用, 有利于改善结直肠癌患者预后, 提高生活质量, 具有较好的临床价值。

英文摘要:

OBJECTIVE To explore the immune function and the influence on the quality of life of Shenqifuzheng injection to stage II/III colorectal cancer patients combined with chemotherapy. METHODS Eighty-nine patients with stage II/III colorectal cancer were randomly divided into the chemotherapy group and combined treatment group. The chemotherapy group accepted FOLFOX4 chemotherapy and combination therapy group were treated with FOLFOX4 chemotherapy plus Shenqifuzheng injection. Karnofsky score was recorded, cellular immune function index (detection CD₃⁺, CD₄⁺, CD₈⁺ T cells and NK cells (CD₁₆⁺, CD₅₆⁺) and the percentage of CD₄⁺/CD₈⁺ ratio, IgG, IgA and IgM) and chemotherapy adverse reaction was observed. RESULTS Karnofsky score displayed that combined treatment group had better curative effect than the chemotherapy group(P<0.01). After seven days of treatment, CD₃⁺, CD₄⁺, CD₄⁺/CD₈⁺, NK, IgG, IgA and IgM in the combination group were higher than the chemotherapy group(P<0.05), CD₈⁺ had no obvious difference. The immunoglobulin in combination group was significantly higher than the chemotherapy group. The adverse reaction of chemotherapy in combination group was less and relatively lighter, which were mainly I-II level. The adverse reaction of the two groups had significant difference (P<0.05). CONCLUSION Shenqifuzheng injection can reduce adverse reaction of chemotherapy with FOLFOX4 with II/III stage colorectal carcinoma, improve the body function and improve their cellular immune function, thus improving patients on chemotherapy adherence to chemotherapy, the coordination function, to improve prognosis in patients with colorectal cancer, improve the quality of life, and has a good clinical value.

